In this episode, Paul E. Sax, MD, discusses the latest recommendations and options for HIV pre-exposure prophylaxis (PrEP), including:CDC PrEP guideline 2021 updates for oral PrEPThe ANRS IPERGAY study: on-demand oral emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) PrEP in men who have sex with men who are at high risk for HIV infectionA review of the HPTN 083 and 084 studies: efficacy and safety of long-acting (LA) injectable cabotegravir (CAB) vs daily oral FTC/TDF for PrEP1-year follow-up after unblinding for HPTN 083 and 084LA CAB for PrEP: monitoring and safetyStopping LA CAB for PrEPPresenter: Paul E. Sax, MDClinical DirectorHIV Program and Division of Infectious DiseasesBrigham and Women’s HospitalProfessor of MedicineHarvard Medical SchoolBoston, MassachusettsLink to full program:https://bit.ly/3VIsDTgFollow along with the slides at:https://bit.ly/3Gh9AKG